AG 2026
Category: 2026
Transgene Provides Business and Financial Update for Q1 2026
Q1 2026
First Half 2026 Financial Results
Synthetic Genome Shuffling of Poxviruses via Yeast TAR Cloning for Next-Generation Oncolytic Platforms
A. Agaoua et al. International Oncolytic Virus Conference 2026 – Download the Abstract – Download the Poster
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
TG4050
Transgene to Participate in Upcoming Investor Meetings
Investor meetings
Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer
Licence Agreement
TG4050, an Individualized Neoantigen Therapeutic Vaccine in Early-Stage Cancer Treatment
K. Bidet-Huang World Vaccine Congress 2026 – Download the Oral Presentation
Transgene to Deliver an Oral Presentation on its Individualized Neoantigen Therapeutic Vaccine TG4050 at the World Vaccine Congress
WVC 2026